AI MARKET SCANNING

BridgeBio Pharma, Inc.

🏛️ NASDAQ 📁 Healthcare 🏭 Biotechnology
AVG HISTORICAL GAP +0.48%
MAX GAP RECORD -9.57%
🔒 PRO INSTITUTIONAL AI PREDICTIVE WIN RATE
94.2%
REVEAL PRO DIRECTION ⚡

SENTINEL HISTORICAL GAP VIEWER

// $BBIO
📊 1-YEAR TIMELINE (GAPS PLOTTED) 🔮 SIMULATE SETUP 🔒
Bullish Opening Gap Bearish Opening Gap T-1 Close Baseline

CATALYSTS & GAP HISTORY

Aug 10, 2026 Earnings Release 2026-08-10 (AFTER CLOSE)
+2.78%
May 07, 2026 Earnings Release 2026-05-07 (AFTER CLOSE)
-1.36%
Feb 24, 2026 Earnings Release 2026-02-24 (AFTER CLOSE)
+3.21%
Oct 29, 2025 Earnings Release 2025-10-29 (AFTER CLOSE)
-0.83%
Aug 05, 2025 Earnings Release 2025-08-05 (AFTER CLOSE)
-9.57%
Apr 29, 2025 Earnings Release 2025-04-29 (AFTER CLOSE)
+6.01%
Feb 20, 2025 Earnings Release 2025-02-20 (BEFORE OPEN)
+8.57%
Nov 12, 2024 Earnings Release 2024-11-12 (BEFORE OPEN)
+0.15%

VOLATILITY & GAP BIAS

AVG GAP MOVE 2.6%
Bullish Gaps (5)
Bearish Gaps (4)
Neutral / Flat (6)

QUANTITATIVE LIVE RADAR BLOTTER

Algorithmic execution stream for $BBIO

EXECUTIONS1 LOGS
STATUS🔒 ENCRYPTED
Execution Date Strategy & Setup Direction Execution Range Hold Time Net PnL
2026-10-22 🔒 PRO RADAR ••• x• $•••.•• → $•••.•• 1269m +1.45%
🔒 Real-Time Strategy Telemetry Protected

Exact execution levels, Trailing Stops, and live bot signals are reserved for PRO members.

UNLOCK LIVE RADAR ⚡

📖 Intelligence Summary

BridgeBio Pharma, Inc., a biopharmaceutical company, discovers, develops, and delivers medicines for patients with genetic diseases. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or transthyretin-mediated amyloidosis (ATTR-CM); Fosdenopterin, an intravenous formulation of synthetic cyclic pyranopterin monophosphate for the…

NEXT UPCOMING PREDICTIVE SIGNAL
STRONG BUY / TARGET +35%
🔓 REVEAL AI SIGNAL & TARGETS ↗